In U.S. Health Care, It’s Still the Prices, Stupid – But Transparency and Consumer Behavior Aren’t Working As Planned
Health Populi
JANUARY 18, 2019
First, a Wall Street Journal profile of Bluebird Bio , a biotech firm that plans to sell gene-replacement therapy extending annual payments to patients based on whether the drug is effective. As the Harvard Chan-POLITICO study points out, prescription drug costs are top-of-mind for health consumers in America.
160 
Let's personalize your content